MedTrace Logo

Evaluation of FID 114657 in Sjogren's Syndrome Subjects

NCT01079871 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2012-02-02

No results posted yet for this study

Summary

The primary objective of this study is to assess the overall Sjogren's Syndrome subject's preference for a particular product. Dry eye symptom relief will also be evaluated based on clinical evaluation and a set of subject questionnaires.

Conditions

  • Sjogren's Syndrome

Interventions

OTHER

FID 114657 (ORB Preserved Ocular Emulsion)

Patients will dose as needed throughout the day (PRN) for 4 weeks.

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01079871 on ClinicalTrials.gov